All News

Originally posted on MartechSeries. The innovative augmentative wearable device, Hapbee, has been giving testers a reason to be happy. With the ability to allow users...

Internet Stock Review Blast from the past scores big! We added VirnetX (VHC) to the Watch List (Patent Stock Review, since shuttered) back in 2010....

IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting. $2.00 to $10 in...

Fortress Bio (FBIO) Inches Closer to $3.00 on Major News. Citius Pharma (CTXR) Inches Closer to the Next Phase III Data Announcement. Citius Pharma Presenting at...

A World Health Organization (WHO) report released April 2014 stated, "this serious threat is no longer a prediction for the future, it is happening right now...

PHASE III PROGRESS October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019 - Data Analysis Back, Results Positive.February...

Dawson James Broker/Dealer Updates. Price Target Remains at $7.00. "OK, So what’s Next? Topline data from the superior efficacy interim analysis should represent the next...

Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop the spread of coronavirus and to...

Is this today's version of the Nifty 50? Microsoft $1.3 Trillion Apple $1.3 Trillion Google $1 Trillion Amazon $1 Trillion Biotech Stock Review: Biotech 5 Pack. 5 Biotech Stocks...

Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially improve the...